| Literature DB >> 28253375 |
Peter J Kerr1,2, Isabella M Cattadori3, Matthew B Rogers4, Adam Fitch4, Adam Geber5, June Liu2, Derek G Sim3, Brian Boag6, John-Sebastian Eden1, Elodie Ghedin5, Andrew F Read3,7, Edward C Holmes1.
Abstract
The co-evolution of myxoma virus (MYXV) and the European rabbit occurred independently in Australia and Europe from different progenitor viruses. Although this is the canonical study of the evolution of virulence, whether the genomic and phenotypic outcomes of MYXV evolution in Europe mirror those observed in Australia is unknown. We addressed this question using viruses isolated in the United Kingdom early in the MYXV epizootic (1954-1955) and between 2008-2013. The later UK viruses fell into three distinct lineages indicative of a long period of separation and independent evolution. Although rates of evolutionary change were almost identical to those previously described for MYXV in Australia and strongly clock-like, genome evolution in the UK and Australia showed little convergence. The phenotypes of eight UK viruses from three lineages were characterized in laboratory rabbits and compared to the progenitor (release) Lausanne strain. Inferred virulence ranged from highly virulent (grade 1) to highly attenuated (grade 5). Two broad disease types were seen: cutaneous nodular myxomatosis characterized by multiple raised secondary cutaneous lesions, or an amyxomatous phenotype with few or no secondary lesions. A novel clinical outcome was acute death with pulmonary oedema and haemorrhage, often associated with bacteria in many tissues but an absence of inflammatory cells. Notably, reading frame disruptions in genes defined as essential for virulence in the progenitor Lausanne strain were compatible with the acquisition of high virulence. Combined, these data support a model of ongoing host-pathogen co-evolution in which multiple genetic pathways can produce successful outcomes in the field that involve both different virulence grades and disease phenotypes, with alterations in tissue tropism and disease mechanisms.Entities:
Mesh:
Year: 2017 PMID: 28253375 PMCID: PMC5349684 DOI: 10.1371/journal.ppat.1006252
Source DB: PubMed Journal: PLoS Pathog ISSN: 1553-7366 Impact factor: 6.823
Fig 1Evolutionary history of MXYV.
(A) Maximum clade credibility (MCC) tree of 57 isolates of MYXV from the Australian and European epizootics including a sequence from Spain [23], four from Germany and one from Poland [24]. Sequence labels are color-coded to reflect virulence grade: grade 1, 2 = red, grade 3 = green, grade 4–5 = blue, non-quantified grade = black. The Lausanne and SLS progenitor strains are shown in bold italic. Tip times reflect the year of sampling. Estimated times to common ancestry are shown for key nodes and posterior probability values greater than 0.95 are marked by the * symbol. The different lineages of UK lineages are marked. (B) Regression of root-to-tip MYXV genetic distances against the year of sampling. Australian viruses are shaded blue and those from Europe in yellow. (C) Bayesian estimates of substitution rate utilizing different evolutionary models: A = Australian viruses, HKY+Γ nucleotide substitution model, relaxed clock, constant population size; B = Australian viruses, HKY+Γ, strict clock, constant population size; C = European viruses, HKY+Γ, relaxed clock, constant population size; D = European viruses, HKY+Γ, strict clock, constant population size; E = All viruses, GTR+Γ, relaxed clock, Bayesian skyride; F = All viruses, HKY+Γ, relaxed clock, constant population size; G = All viruses, HKY+Γ, relaxed clock, Bayesian skyride; H = All viruses, HKY+Γ, strict clock, constant population size (shown in red as this was used to infer the MCC tree); I = All viruses, HKY+Γ, strict clock, Bayesian skyride.
Viruses sequenced in this study.
| Virus designation | Sampling date |
|---|---|
| Belfast/1955 | 1955 |
| Perthshire 1526 | 17/09/2008 |
| Perthshire 1527 | 17/09/2008 |
| Perthshire 1529 | 17/09/2008 |
| Perthshire 1537 | 17/09/2008 |
| Perthshire 1754 | 14/07/2009 |
| Perthshire 1756 | 14/07/2009 |
| Perthshire 1792 | 02/08/2009 |
| Perthshire 1812 | 10/08/2009 |
| Perthshire 1818 | 10/08/2009 |
| Perthshire 2080 | 15/10/2010 |
| Perthshire 2082 | 15/10/2010 |
| Perthshire 2256 | 20/09/2011 |
| Perthshire 2272 | 26/09/2011 |
| Perthshire 2282 | 15/10/2011 |
| Perthshire 2409 | 30/8/2012 |
| Perthshire 2427 | 19/9/2012 |
| Perthshire 2428 | 19/9/2012 |
| Perthshire 2524 | 29/9/2013 |
| Yorkshire 127 | 31/12/2008 |
| Yorkshire Col | 08/03/2011 |
| Yorkshire 135 | 02/11/2009 |
Fig 2Mutation analysis in MYXV.
(A) The number of mutations per gene (y-axis) in all viruses from the UK. (B) The number of mutations per gene (y-axis) in all viruses from Australia [21]. In each graph, blue lines represent the number of non-synonymous mutations, red lines represent synonymous mutations, and green lines represent indels (any insertion/deletion event was counted as a single event). (C) The total number of synonymous, non-synonymous and indel mutations per gene was standardised by dividing by the gene length. The resulting mutational frequency for each gene was plotted for UK and Australia. The red lines indicate the median mutation frequencies for the UK and Australia (which were not significantly different). The blue diagonal line indicates equal mutation frequencies for the UK and Australia. Selected individual genes are indicated.
Gene disruptions in the UK isolates of MYXV.
| Gene | Protein function | Mutation | virus |
|---|---|---|---|
| Premature stop amino acid 174; retains antiapoptosis; loses secreted TNF binding | Perthshire 1526; 1527; 1529; 1537 | ||
| unknown | Premature stop amino acid 66 | Perthshire 2272 | |
| Antiapoptosis | Premature stop amino acid 141; loss of C-terminal RDEL motif | Perthshire lineage 1 | |
| Antiapoptosis/E3 Ub ligase complex | Altered amino acid sequence >401 & premature stop at 471; loss of functional C-terminal F-box motif | Yorkshire lineage | |
| E3 Ub ligase complex | Altered amino acid sequence >361 and premature stop at 421 | Perthshire 2082 | |
| Secreted serine proteinase inhibitor (SERPIN) | Premature stop amino acid 268 deletes active site | Perthshire 2409 | |
| E3 Ub ligase complex | Premature stop amino acid 192 and amino acid 508 | Perthshire lineage 1 | |
| E3 Ub ligase complex | Premature stop amino acid 288 | Yorkshire Col; Yorkshire 135 | |
| E3 Ub ligase complex | Premature stop amino acid 348 | Yorkshire 127 | |
| VACV F8L (cytoplasmic protein) | Premature stop amino acid 46 (normal 66) | Yorkshire 127 | |
| VACV O1L orthologue | Premature stop aa 442 | Sussex (1954); Nottingham (1955) | |
| VACV O1L orthologue | Premature stop amino acid 441 | Perthshire lineage 1 & 2 | |
| VACV O1L orthologue | Premature stop amino acid 338 | Perthshire lineage 2 | |
| Structural? | Premature stop amino acid 1953 | Nottingham (1955) | |
| Immunomodulatory | Premature stop amino acid 69 | Perthshire 1527 | |
| E3 Ub ligase complex | Premature stop amino acid 170 | Perthshire lineage 2 | |
| NF-κB inhibition; E3 Ub ligase complex | Premature stop amino acid 196 | Nottingham (1955) | |
| E3 Ub ligase complex/MHC-1 downregulation | Premature stop amino acid 118; loss of conserved domain | Perthshire lineage 1; Yorkshire lineage |
1Shaded cells represent genes implicated in MYXV virulence.
Clinical phenotypes of UK MYXV isolates.
| Virus | Normalized average survival time (AST) days; (case fatality rate; CFR) | Unnormalized survival time estimates (range) days | Inferred virulence grade | Disease phenotype |
|---|---|---|---|---|
| Lausanne | 12.5 (6/6) | 12.1–13.2 | 1 | nodular |
| Perthshire 1792 | 15.9 (6/6) | 12.6–22 | 2 | amyxomatous |
| Yorkshire Col | 15.7 (6/6) | 12.7–20 | 2 | amyxomatous |
| Perthshire 2082 | 17.9 (6/6) | 14.6–22 days | 3A | amyxomatous |
| Perthshire 2282 | 20.7 (5/6) | 13–>26 (S?) | 3A | amyxomatous |
| Yorkshire 127 | 15.3s (5/6) | 11.6 –S | 2/3A | nodular |
| Yorkshire 135 | 9.1 (6/6) | 7.6–12.6 | 1 | amyxomatous |
| Perthshire 1537 | 17.1 (4/6) | 11–>26 (S? S?) | 3A/4 | amyxomatous or nodular |
| Perthshire 1527 | n/a (1/6) | n/a | 5 | nodular |
1 [43].
2 possible survivor.
3 recovered.
4 based on AST/CFR.
Fig 3Kaplan-Meier survival plots.
(A) Perthshire lineage 1. There is a statistically significant difference between Perthshire 1792 and Perthshire 1527 (p = 0.0035; log rank test), but not between Perthshire 1527 and Perthshire 1537 (p = 0.11) nor between Perthshire 1792 and Perthshire 1537 (p = 0.79). (B) Perthshire lineage 2. There is no significant difference between the two viruses studied (p = 0.25). (C) Yorkshire lineage. There is a significant difference between Yorkshire 135 and Yorkshire Col (p = 0.0015) and Yorkshire 135 and Yorkshire 127 (p = 0.019), but not between Yorkshire col and Yorkshire 127 (p = 0.53). (D) Lausanne. There is a significant difference in survival time between Yorkshire 135 and Lu (p = 0.013).
Fig 4Acute collapse syndrome.
(A) Epidermal hemorrhages 1–2 cm in diameter developed over 4–5 hours in the epidermis (Yorkshire Col day 12). (B) Severe pulmonary oedema with fluid and froth filling the trachea (arrowed) and bronchi and swollen wet lungs (Perthshire 2082 day 15). (C) Hemorrhages (arrowed) in lungs (Perthshire 2082 day 14). (D) Bacteria (arrows) in pulmonary blood vessels (Perthshire 2082 day 15; scale bar 20 μm). (E) Popliteal lymph node showing complete loss of lymphocytes and massive numbers of bacteria (arrows) staining purple throughout the sinuses (Perthshire 2282 day 12; scale bar 200 μm). (F) Hind leg muscle showing bacteria (arrows) in blood vessels (Perthshire 2282 day 12; scale bar 20 μm).
Fig 5Nodular and amyxomatous phenotypes.
(A) Lu day 10: grossly swollen almost granulomatous eyelids and swollen drooping ears; note the large swelling at the base of the ears. (B) Perthshire 1527 day 10; secondary lesions on ears but otherwise mild clinical signs with this grade 5 virus. (C) Perthshire 1537 day 10: moderately swollen ears, eyelids and head. Despite the alert appearance and mild clinical signs, the rabbit died with acute collapse less than 24 hours later. (D) Lu day 10: domed primary lesion oozing at top. (E) Lu day 12: section through primary lesion. (F) Perthshire 1792 day 10: amyxomatous phenotype showing very limited reaction at inoculation site. (G) Lu: histology of upper part of primary lesion day 12. Destruction of epidermis and dermis with scab formation and hemorrhage (arrowed); H: remnant hair follicle. (H) Lu primary lesion–deeper within the same lesion; short arrow indicates blue-grey staining mucinous material; long arrow indicates muscle necrosis and inflammatory cells (neutrophils). (I) Perthshire 2282 day 14: histopathology of primary lesion; note relatively normal architecture with some hyperplasia of epidermis and disruption of collagen fibres in dermis. E: epidermis; D: dermis; H: hair follicle. Scale bars = 100 μm.
MYXV virulence classification.
| 1Grade 1 | Grade 2 | Grade 3A | Grade 3B | Grade 4 | Grade 5 | |
|---|---|---|---|---|---|---|
| CFR | >99 | 95–99 | 90–95 | 70–90 | 50–70 | <50 |
| AST | ≤ 13 | 14–16 | 17–22 | 23–28 | 29–50 | n/a |